Last C$2.16 CAD
Change Today -0.21 / -8.86%
Volume 28.4K
MPH On Other Exchanges
As of 3:21 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

medicure inc (MPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/14 - C$3.15
52 Week Low
12/23/13 - C$0.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDICURE INC (MPH)

Related News

No related news articles were found.

medicure inc (MPH) Related Businessweek News

No Related Businessweek News Found

medicure inc (MPH) Details

Medicure Inc., a biopharmaceutical company, researches, develops, and commercializes human therapeutics in Canada, Barbados, and the United States. The company markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT HDB, a high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. It also develops Tardoxal, which is in Phase IIa clinical trial for the treatment of tardive dyskinesia/neurological indications; and Transdermal AGGRASTAT that is in a preclinical stage for acute cardiology. In addition, the company offers novel therapeutics comprising a series of small molecule dual acting anticoagulant/antiplatelet compounds to treat venous and arterial thrombosis. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.

Founded in 1997

medicure inc (MPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medicure inc (MPH) Key Developments

Medicure Inc. Reports Consolidated Earnings Results for the First Quarter Ended August 31, 2014

Medicure Inc. reported consolidated earnings results for the first quarter ended August 31, 2014. The company recorded net revenue of CAD 2,125,483 compared to CAD 747,018 previous fiscal year, an increase of 185%. Earnings before interest, taxes, depreciation and amortization was CAD 605,000 compared to a loss of CAD 233,000 previous fiscal year. The increase in EBITDA is primarily due to higher net revenues, partially offset by higher selling, general and administration expenses due to higher personnel expenses and selling costs associated with the growth in AGGRASTAT revenues, as well as stock-based compensation expenses relating to stock options granted during the quarter. Net income was CAD 1,347,471 or CAD 0.10 per share compared to a net loss of CAD 502,000 or CAD 0.04 per basic and diluted share a year ago. Included in net income is CAD 1.1 million of other income relating to the value of Medicure's ownership interest in Apicore Inc. acquired on July 3, 2014, net of costs associated with the transaction, as a result of services provided by Medicure in its lead role in structuring a majority interest purchase and financing of Apicore. Excluding this other income, net income for the quarter would have been CAD 215,000, an increase of CAD 717,000 from the net loss of CAD 502,000 experienced in the same quarter of the previous fiscal year. This increase is primarily a result of increased revenues, partially offset by higher selling, general and administration expenses. Operating income was CAD 462,802 against operating loss of CAD 370,702 a year ago. Cash flows from operating activities was CAD 283,032 against cash flows used in operating activities of CAD 114,403 a year ago. Acquisitions of property and equipment was CAD 8,768.

Medicure Inc., Q1 2015 Earnings Call, Oct 17, 2014

Medicure Inc., Q1 2015 Earnings Call, Oct 17, 2014

Medicure Inc. Auditor Raises 'Going Concern' Doubt

Medicure Inc. filed its 6-K on Sep 11, 2014 for the period ending May 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MPH:CN C$2.16 CAD -0.21

MPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.05 USD +0.28
Allergan Inc/United States $212.63 USD +0.45
Eli Lilly & Co $72.40 USD -0.05
Merck KGaA €78.43 EUR +0.316
Medicines Co/The $27.31 USD +0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation MPH Industry Range
Price/Earnings 100.0x
Price/Sales 3.8x
Price/Book NM Not Meaningful
Price/Cash Flow 117.3x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICURE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at